Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Development partner sought for new wound dressing

Feb. 12, 1997

Teva presents potential antipsoriatic agents

Feb. 12, 1997

Tretinoin gel cleared for marketing by FDA

Feb. 11, 1997

Tsumura describes agents for dermatitis

Feb. 7, 1997

Hyal's Solarase submitted for approval

Feb. 5, 1997

Bone morphogenic protein-10 claimed by Human Genome Sciences

Feb. 5, 1997

Patent coverage sought for novel approach to reducing side effects of vitamin A

Feb. 4, 1997

Allergan continues research into retinoids and retinoid-like compounds

Feb. 3, 1997

Preclinical results support Pharmadigm's DHEA development program

Jan. 31, 1997

Pierre Fabre to market Penederm OTC product

Jan. 30, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.